NA
ETON icon

Navellier & Associates’s Eton Pharmaceutcials ETON Stock Holding History

Navellier & Associates’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$652K Buy
+18,010
New +$528K 0.05% 217
2025
Q4 		– Sell
-17,494
Closed -$380K – 351
2025
Q3 		$380K Buy
+17,494
New +$290K 0.04% 290

Other funds holding ETON

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
LK
Lumbard & Kellner Hollis, New Hampshire $330M AUM 65.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.56B AUM 21.74% 1-Year Est. Return

Navellier & Associates's ETON Position: Q2 2026 in Review

Navellier & Associates opened a new position in Eton Pharmaceutcials (ETON) in Q2 2026: 18,010 shares worth $652K. The stake represents 0.05% of the portfolio and ranks #217 among its holdings. This is a return to the name: Navellier & Associates previously reported a position in ETON as recently as Q3 2025.

Navellier & Associates first reported a position in ETON in Q3 2025 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • Navellier & Associates held 18,010 shares of Eton Pharmaceutcials worth $652K as of Q2 2026.
  • Eton Pharmaceutcials was a new Navellier & Associates position in Q2 2026.
  • Eton Pharmaceutcials made up 0.05% of Navellier & Associates's portfolio in Q2 2026, its #217 holding.
  • Navellier & Associates first reported a position in Eton Pharmaceutcials in Q3 2025 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.